MedTrace Logo

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

NCT05541107 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 270

Last updated 2022-09-15

No results posted yet for this study

Summary

This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).

Conditions

  • Cryptococcal Meningitis

Interventions

DRUG

MAT2203

oral lipid nanocrystal amphotericin B

DRUG

Amphotericin B

Intravenous Amphotericin B

Sponsors & Collaborators

Principal Investigators

  • David R Boulware, MD · University of Minnesota

  • David B Meya, MBChB · Infectious Diseases Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2024-10-31
Completion
2025-01-31
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05541107 on ClinicalTrials.gov